Midodrine-d6 HCl | CAS#1188265-43-1 | Midodrine internal standard

MedKoo Cat#: 464945 | Name: Midodrine-d6 HCl

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Midodrine-d6 is intended for use as an internal standard for the quantification of midodrine by GC- or LC-MS. Midodrine is a prodrug form of the α1-adrenergic receptor (α1-AR) agonist desglymidodrine. It is converted to desglymidodrine by enzymatic hydrolysis. Midodrine (5 mg/kg) increases mean arterial pressure (MAP) and decreases heart rate in normotensive rats.2 Formulations containing midodrine have been used in the treatment of orthostatic hypotension.

Chemical Structure

Midodrine-d6 HCl

CAS#1188265-43-1

Theoretical Analysis

MedKoo Cat#: 464945

Name: Midodrine-d6 HCl

CAS#: 1188265-43-1

Chemical Formula: C12H13D6ClN2O4

Exact Mass: 296.1410

Molecular Weight: 296.78

Elemental Analysis: C, 48.57; H, 8.49; Cl, 11.94; N, 9.44; O, 21.56

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 750.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Midodrine-d6 HCl; Midodrine d6 HCl; Midodrine-d6 hydrochloride; Midodrine d6 hydrochloride;

IUPAC/Chemical Name

2-amino-N-(2-(2,5-bis(methoxy-d3)phenyl)-2-hydroxyethyl)acetamide hydrochloride

InChi Key

MGCQZNBCJBRZDT-TXHXQZCNSA-N

InChi Code

InChI=1S/C12H18N2O4.ClH/c1-17-8-3-4-11(18-2)9(5-8)10(15)7-14-12(16)6-13;/h3-5,10,15H,6-7,13H2,1-2H3,(H,14,16);1H/i1D3,2D3;

SMILES Code

NCC(NCC(O)C1=C(OC([2H])([2H])[2H])C=CC(OC([2H])([2H])[2H])=C1)=O.Cl

Appearance

Solid powder

Purity

>99% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 296.78 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Kim E, Kast C, Afroz-Hossain A, Qiu M, Pappas K, Sinvani L. Bridging the Gap Between the Intensive Care Unit and the Acute Medical Care Unit. Am J Crit Care. 2021 May 1;30(3):193-200. doi: 10.4037/ajcc2021591. PMID: 34161979. 2: Al-Abdouh A, Haddadin S, Matta A, Jabri A, Barbarawi M, Abusnina W, Radideh Q, Mhanna M, Suffredini DA, Michos ED. Impact of Adjuvant Use of Midodrine to Intravenous Vasopressors: A Systematic Review and Meta-Analysis. Crit Care Res Pract. 2021 May 15;2021:5588483. doi: 10.1155/2021/5588483. PMID: 34055408; PMCID: PMC8147551. 3: Sharma P, Puri P, Bansal N, Singla V, Kumar A, ShriHari AA, Arora A. Midodrine and albumin versus albumin alone for the secondary prophylaxis of acute kidney injury in a patient with cirrhosis and ascites. Eur J Gastroenterol Hepatol. 2021 May 21. doi: 10.1097/MEG.0000000000002154. Epub ahead of print. PMID: 34034268. 4: Tamaoka S, Osada A, Kin T, Arimitsu T, Hida M. Midodrine, an Oral Alpha-1 Adrenoreceptor Agonist, Successfully Treated Refractory Congenital Chylous Pleural Effusion and Ascites in a Neonate. Chest. 2021 Apr;159(4):e189-e191. doi: 10.1016/j.chest.2020.10.071. Epub 2021 Apr 6. PMID: 34022016. 5: Lal A, Trivedi V, Rizvi MS, Amsbaugh A, Myers MK, Saleh K, Kashyap R, Gajic O. Oral Midodrine Administration During the First 24 Hours of Sepsis to Reduce the Need of Vasoactive Agents: Placebo-Controlled Feasibility Clinical Trial. Crit Care Explor. 2021 May 6;3(5):e0382. doi: 10.1097/CCE.0000000000000382. PMID: 33977276; PMCID: PMC8104269. 6: Macielak SA, Vollmer NJ, Haddad NA, Nabzdyk CGS, Nei SD. Hemodynamic Effects of an Increased Midodrine Dosing Frequency. Crit Care Explor. 2021 Apr 26;3(4):e0405. doi: 10.1097/CCE.0000000000000405. PMID: 33912835; PMCID: PMC8078337. 7: Rocha EA, Mehta N, Távora-Mehta MZP, Roncari CF, Cidrão AAL, Elias Neto J. Dysautonomia: A Forgotten Condition - Part 1. Arq Bras Cardiol. 2021 Apr;116(4):814-835. English, Portuguese. doi: 10.36660/abc.20200420. PMID: 33886735; PMCID: PMC8121406. 8: Davoudi-Monfared E, Mohammadi M, Khoshavi M, Khalili H. The effect of midodrine on lactate clearance in patients with septic shock: a pilot study. J Comp Eff Res. 2021 Jun;10(8):673-683. doi: 10.2217/cer-2020-0238. Epub 2021 Apr 16. PMID: 33860672. 9: Kwong A, Kim WR, Kwo PY, Wang U, Cheng X. Feasibility and Effectiveness of Norepinephrine Outside the Intensive Care Setting for Treatment of Hepatorenal Syndrome. Liver Transpl. 2021 Apr 10. doi: 10.1002/lt.26065. Epub ahead of print. PMID: 33837624. 10: Byran G, Ashwini J, Lakshmanan K, Rajagopal K, Subramanian G, Sn M. New stability chiral RP-HPLC method for degradation products determination in midodrine hydrochloride. Drug Dev Ind Pharm. 2021 Apr 5:1-21. doi: 10.1080/03639045.2021.1908340. Epub ahead of print. PMID: 33818229. 11: Idiaquez JF, Idiaquez J, Casar JC, Biaggioni I. Neurogenic Orthostatic Hypotension. Lessons From Synucleinopathies. Am J Hypertens. 2021 Mar 11;34(2):125-133. doi: 10.1093/ajh/hpaa131. PMID: 33705537; PMCID: PMC7951046. 12: Aminorroaya A, Tavolinejad H, Sadeghian S, Jalali A, Alaeddini F, Emkanjoo Z, Mollazadeh R, Bozorgi A, Oraii S, Kiarsi M, Shahabi J, Akbarzadeh MA, Rahimi B, Joharimoghadam A, Mohsenizade A, Mohammadi R, Oraii A, Ariannejad H, Apakuppakul S, Ngarmukos T, Tajdini M. Comparison of Outcomes with Midodrine and Fludrocortisone for Objective Recurrence in Treating Syncope (COMFORTS trial): Rationale and design for a multi-center randomized controlled trial. Am Heart J. 2021 Jul;237:5-12. doi: 10.1016/j.ahj.2021.03.002. Epub 2021 Mar 6. PMID: 33689731. 13: Isaacson SH, Dashtipour K, Mehdirad AA, Peltier AC. Management Strategies for Comorbid Supine Hypertension in Patients with Neurogenic Orthostatic Hypotension. Curr Neurol Neurosci Rep. 2021 Mar 9;21(4):18. doi: 10.1007/s11910-021-01104-3. PMID: 33687577; PMCID: PMC7943503. 14: Midodrine for orthostatic hypotension. Aust Prescr. 2021 Feb;44(1):31. doi: 10.18773/austprescr.2020.081. Epub 2020 Dec 17. PMID: 33664549; PMCID: PMC7900270. 15: Asai Y, Sato T, Kito D, Yamamoto T, Hioki I, Urata Y, Abe Y. Combination therapy of midodrine and droxidopa for refractory hypotension in heart failure with preserved ejection fraction per a pharmacist's proposal: a case report. J Pharm Health Care Sci. 2021 Mar 3;7(1):10. doi: 10.1186/s40780-021-00193-z. PMID: 33653416; PMCID: PMC7927230. 16: Shuroog J, Canakis J, Khan FJ, Suryanarayana P, Soherwardi S. A Rare Case of Mass-Like Hypertrophic Cardiomyopathy. Cureus. 2021 Jan 19;13(1):e12787. doi: 10.7759/cureus.12787. PMID: 33628657; PMCID: PMC7891796. 17: Kanbay M, Ertuglu LA, Afsar B, Ozdogan E, Siriopol D, Covic A, Basile C, Ortiz A. An update review of intradialytic hypotension: concept, risk factors, clinical implications and management. Clin Kidney J. 2020 Jul 8;13(6):981-993. doi: 10.1093/ckj/sfaa078. PMID: 33391741; PMCID: PMC7769545. 18: Brignole M, Rivasi G. New insights in diagnostics and therapies in syncope: a novel approach to non-cardiac syncope. Heart. 2021 Jun;107(11):864-873. doi: 10.1136/heartjnl-2020-318261. Epub 2021 Jan 18. PMID: 33462120. 19: Miike H, Ohuchi H, Hayama Y, Isawa T, Sakaguchi H, Kurosaki K, Nakai M. Systemic Artery Vasoconstrictor Therapy in Fontan Patients with High Cardiac Output-Heart Failure: A Single-Center Experience. Pediatr Cardiol. 2021 Mar;42(3):700-706. doi: 10.1007/s00246-020-02532-7. Epub 2021 Jan 8. PMID: 33416919. 20: Santer P, Eikermann M. High-dose midodrine is not effective for treatment of persistent hypotension in the intensive care unit. Intensive Care Med. 2021 Feb;47(2):252-253. doi: 10.1007/s00134-020-06333-7. Epub 2021 Jan 8. PMID: 33416917.